Saudi Arabia's economic, demographic, epidemiological and political factors will shape the provision of healthcare across the nation. Healthcare spending will be greatly boosted by government initiatives. The new health projects will increase access to healthcare and provide revenue-earning opportunities for drugmakers, medical device companies and healthcare service providers. The government's planned privatisation of the healthcare industry will increase investment in the sector, with greater transparen cy attracting foreign companies .
Headline Expenditure Projections
* Pharmaceuticals: SAR22.70bn (USD6.06bn) in 2013 to SAR24.79bn (USD6.62bn) in 2014; +9.2% in both local currency and US dollar terms. Forecast unchanged from Q314 .
* Healthcare: SAR94.20bn (USD25.15bn) in 2013 to SAR102.58bn (USD27.39bn) in 2014; +8.9% in both local currency and US dollar terms. Forecast unchanged from Q314 .
Full Report Details at
- http://www.fastmr.com/prod/888171_saudi_arabia_pharmaceuticals_healthcare_report_q4.aspx?afid=301
Risk/Reward Rating
In our Q414 RRR matrix, Saudi Arabia maintains its leading position of the 30 Middle East and Africa (MEA) markets in the region. Its high composite score is due to its wealth and sizeable population, which will support the longer-term development of its pharmaceutical market. Furthermore, its forecast growth rate is high due to favourable public and private healthcare investments. The government is also in the process of creating more public-private health partnerships and encouraging private health insurance uptake, which should provide momentum for drug sales. However, Saudi Arabia's commitment to intellectual property (IP) protection remains a major issue for foreign research-based pharmaceutical players.
Key Trends And Developments
* In June 2014, Pfizer entered into a manufacturing and licensing agreement with Tabuk Pharmaceuticals. The Riyadh-headquartered firm has the rights to manufacture, distribute and commercialise four innovative medicines in Saudi Arabia's USD6.1bn pharmaceutical market.
* In June 2014, Saudi Arabia...
The Saudi Arabia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Saudi Arabia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Saudi pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Saudi Arabia to test other views - a key input for successful budgeting and strategic business planning in the Saudi pharmaceutical and healthcare market.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
You may also be interested in these related reports:
- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2014
- Argentina Pharmaceuticals & Healthcare Report Q4 2014
Saudi Arabia Pharmaceuticals & Healthcare Report Q4 2014 - New Market Study Published
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001